HIV Vaccine Challenges: Mutation, Immune Evasion & Research Directions

Despite 40+ years, no effective HIV vaccine exists. Key barriers:

Major Scientific Hurdles

  1. Extreme genetic diversity: Error-prone RT → quasispecies; multiple clades (A–K), recombinants. Vaccine must cover global variants.
  2. No natural sterilizing immunity: No human clears HIV; no correlate of protection to mimic.
  3. Immune evasion: Glycan shield on Env, variable loops, Nef/Vpu downregulation of MHC-I, latency in reservoirs.
  4. Inadequate animal models: SIV/SHIV in macaques imperfectly mimics HIV pathogenesis.
  5. Complex envelope trimer: Metastable, conformationally masked conserved epitopes (CD4bs, V2 apex, MPER, fusion peptide).
  6. Immune tolerance/exhaustion: Chronic antigen → T-cell dysfunction.

Promising Strategies

  • Germline-targeting immunogens: Prime bnAb precursors (e.g., VRC01-class, PGT121-class).
  • mRNA platforms: Rapid iteration, native-like trimers (e.g., Moderna/IAVI trials).
  • Mosaic/consensus sequences: Cover global diversity (Janssen Ad26.Mos4.HIV).
  • T-cell vaccines: Target conserved internal proteins (Gag, Pol) for viral control.
  • Broadly neutralizing antibodies (bnAbs): Passive infusion (VRC01, 3BNC117) + long-acting formulations.

Progress is incremental; combination approaches likely needed.

HIV & AIDS - Related Articles